Janux Therapeutics, Inc. JANX
We take great care to ensure that the data presented and summarized in this overview for Janux Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JANX
View all-
Ra Capital Management, L.P. Boston, MA11.2MShares$272 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$108 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$70.9 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$61.3 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$53.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.14MShares$52 Million0.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.79MShares$43.5 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.5MShares$36.4 Million3.49% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.47MShares$35.7 Million2.93% of portfolio
Latest Institutional Activity in JANX
Top Purchases
Top Sells
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Transactions at JANX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Winston Kung |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Jake Simson |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Alana B. Mc Nulty |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Natasha Hernday |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+30.05%
|
-
|
|
Jun 11
2025
|
Sheila Gujrathi |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+3.06%
|
-
|
|
Jun 11
2025
|
Eric Dobmeier |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+27.31%
|
-
|
|
Jun 11
2025
|
Vickie L Capps |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+4.82%
|
-
|
|
Jun 11
2025
|
Ronald W Barrett |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,750
+37.5%
|
-
|
|
Jun 02
2025
|
Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,333
-1.96%
|
$106,656
$32.28 P/Share
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+3.75%
|
$13,332
$4.21 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-3.9%
|
$100,020
$30.0 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|
|
Mar 07
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
110,206
+1.08%
|
$3,416,386
$31.02 P/Share
|
|
Mar 06
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
372,093
+3.58%
|
$11,162,790
$30.78 P/Share
|
|
Mar 05
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
341,742
+1.73%
|
$10,252,260
$30.93 P/Share
|
|
Mar 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-1.97%
|
$106,688
$32.36 P/Share
|
|
Mar 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|
|
Feb 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-1.31%
|
$140,028
$42.82 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 292K shares |
|---|---|
| Other acquisition or disposition | 6.92K shares |
| Open market or private purchase | 2.02M shares |
| Exercise of conversion of derivative security | 94.1K shares |
| Open market or private sale | 2.88M shares |
|---|